MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 15.08.2022
La Jolla Pharmaceutical Company Anteile 2011-2026 | LJPC
Anteile Jährlich La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 27.3 M | 27.1 M | 25.4 M | 21.2 M | 17.2 M | 15.7 M | 10.7 M | 454 K | 204 K | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 27.4 M | 204 K | 17.3 M |
Anteile Vierteljährlich La Jolla Pharmaceutical Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 25.3 M | 26.2 M | 26.8 M | 27.5 M | 27.5 M | 27.4 M | 27.4 M | 27.4 M | 27.3 M | 27.2 M | 27.2 M | 27.1 M | 27.1 M | 27 M | 26.3 M | 26.2 M | 26.2 M | 22.7 M | 22.2 M | 22.1 M | 22.1 M | 18.4 M | 17.3 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 14.9 M | 15.3 M | 15.2 M | 15.2 M | 13.6 M | 8.12 M | 5.54 M | 4.4 M | 827 K | 550 K | 17.5 M | 285 K | 13.3 M | 11.6 M | 2.09 M | 875 K | 533 K | 12.4 M | 947 K |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 27.5 M | 285 K | 17.5 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
299 M | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K |  USA |
 |
Aptorum Group Limited
APM
|
5.45 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M | China |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
238 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
AgeX Therapeutics
AGE
|
1.08 K | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
126 M | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
14.7 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
19.3 M | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
224 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
32.7 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
49.7 M | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
207 M | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
192 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.02 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
30.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
663 M | $ 2.69 | -0.74 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
192 M | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
73.4 M | $ 1.23 | -2.38 % | $ 90.3 M | USA |
 |
Cabaletta Bio
CABA
|
1.17 M | $ 3.18 | -0.16 % | $ 3.71 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
39.7 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
116 M | - | -7.23 % | $ 13 M | USA |